Back to Agenda
Demonstration of Biosimilarity: Nonclinical Considerations and Challenges
Session Chair(s)
Mary Ellen Cosenza, PhD, MS, RAC
President
MEC Regulatory & Toxicology Consulting, LLC, United States
The nonclinical studies consist of pharmacology, pharmacokinetics and/or toxicology studies, and while the nonclinical studies are an important component of the biosimilarity exercise, the regulatory authorities generally recommend an abbreviated approach (vs. the traditional nonclinical package) be applied in demonstrating a proposed biosimilar is similar to the reference product. Certain challenges must be addressed when conducting comparative nonclinical studies, including selection of relevant in vitro and/or in vivo models and the development of the analytical assays. This presentation will review the various points that should be considered in designing a nonclinical package as part of the biosimilarity exercise, as well as provide an overview of the challenges that often arise when performing these nonclinical studies.
Speaker(s)
Speaker
Barbara Mounho-Zamora, PhD
ToxStrategies, United States
Biopharmaceuticals/Pharmaceuticals Practice Leader
Have an account?